icipe Digital Repository

Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non‑inferiority trial

Show simple item record

dc.contributor.author Johanna, M. Roth
dc.contributor.author Patrick, Sawa
dc.contributor.author Nicodemus, Makio
dc.contributor.author George, Omweri
dc.contributor.author Victor, Osoti
dc.contributor.author Selpha, Okach
dc.contributor.author Felix, Choy
dc.contributor.author Henk, D. F. H. Schallig
dc.contributor.author Pètra, Mens
dc.date.accessioned 2019-05-09T07:55:44Z
dc.date.available 2019-05-09T07:55:44Z
dc.date.issued 2018
dc.identifier.uri http://hdl.handle.net/123456789/913
dc.description.abstract Background: Pyronaridine–artesunate is a novel artemisinin-based combination therapy. The efficacy and safety of pyronaridine–artesunate were compared with artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children.Methods: This phase III open-label randomized controlled non-inferiority trial was conducted in Western Kenya.Children aged 6 months to ≤ 12 years with a bodyweight > 5 kg and microscopically confirmed P. falciparum malaria were randomly assigned in a 1:1 ratio to orally receive pyronaridine–artesunate or artemether–lumefantrine, dosed according to bodyweight, for 3 days. Results: Of 197 participants, 101 received pyronaridine–artesunate and 96 received artemether–lumefantrine. The day-28 adequate clinical and parasitological response in the per-protocol population, PCR-corrected for reinfections,was 98.9% (93/94, 95% CI 94.2–99.8) for pyronaridine–artesunate and 96.4% (81/84, 95% CI 90.0–98.8) for artemether–lumefantrine. Pyronaridine–artesunate was found to be non-inferior to artemether–lumefantrine: the treatment difference was 2.5% (95% CI − 2.8 to 9.0). Adverse events occurred in 41.6% (42/101) and 34.4% (33/96) of patients in the pyronaridine–artesunate group and the artemether–lumefantrine group, respectively. No participants were found to have alanine or aspartate aminotransferase levels > 3 times the upper limit of normal. Conclusions: Pyronaridine–artesunate was well tolerated, efficacious and non-inferior to artemether–lumefantrine for the treatment of uncomplicated P. falciparum malaria in Kenyan children. Results are in line with previous reports and inclusion of pyronaridine–artesunate in paediatric malaria treatment programmes should be considered.This study is registered at clinicaltrials.gov under NCT02411994. Registration date: 8 April 2015. https ://clini caltr ials.gov/ct2/show/NCT02 41199 4?term=pyron aridi ne–artes unate &cond=Malar ia&cntry =KE&rank=1 en_US
dc.description.sponsorship EU FP7-Health-2013. 0-1 Project “Translation of the direct-on-blood PCR-NALFIA system into an innovative near point-ofcare diagnostic for malaria” (DIAGMAL) [Grant Number 601714]. en_US
dc.rights Attribution-NonCommercial-ShareAlike 3.0 United States *
dc.rights.uri http://creativecommons.org/licenses/by-nc-sa/3.0/us/ *
dc.subject Plasmodium falciparum, Malaria, Paediatric, Pyronaridine–artesunate, Artemether–lumefantrine, Kenya en_US
dc.title Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non‑inferiority trial en_US
dc.type Article en_US


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 United States Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 United States

Search icipe Repository


Advanced Search

Browse

My Account